Table 2 Clinical and modifying characteristics of study participants at Amhara region, Ethiopia, 2021 (n = 406)
Variable | Category | Frequency(n) | Percent (%) |
|---|---|---|---|
Therapy | Monotherapy | 152 | 37.44 |
Poly therapy | 254 | 62.56 | |
Illness duration/ year | ≤ 5 | 329 | 81.03 |
> 5 | 77 | 18.97 | |
Used medication | Carbamazepine | Â | Â |
| Â | Yes | 161 | 39.66 |
| Â | No | 245 | 60.34 |
| Â | Phenobarbital | Â | Â |
| Â | Yes | 186 | 45.81 |
| Â | No | 220 | 54.19 |
| Â | Phenytoin | Â | Â |
| Â | Yes | 244 | 60.10 |
| Â | No | 162 | 39.90 |
| Â | Sodium valproate | Â | Â |
| Â | Yes | 92 | 22.7 |
| Â | No | 314 | 77.3 |
Medication adherence | Good | 249 | 61.3 |
| Â | Poor | 157 | 38.7 |
Comorbidity | Yes | 92 | 22.7 |
No | 314 | 77.34 | |
seizure frequency/ month | None | 14 | 3.45 |
1–2 | 258 | 63.55 | |
|  | 3–5 | 134 | 33.00 |
Type of seizure | Focal | 3 | 0.74 |
Generalized | 403 | 99.26 | |
Use of substance | Yes | 87 | 21.43 |
No | 319 | 78.57 | |
Stigma | Yes | 209 | 51.48 |
No | 197 | 48.52 | |
Level of social support | Poor | 128 | 31.53 |
Moderate | 67 | 16.50 | |
Strong | 211 | 51.97 |